The Emirates Drug Establishment (EDE) has announced the activation of a new regulatory mechanism requiring pharmaceutical companies to appoint more than one agent for each medical product registered in the UAE, in a move aimed at ending monopolistic practices and strengthening national drug security.
The measure, described as the first of its kind in the UAE healthcare sector, is designed to ensure the continuous availability of medicines and medical products while reducing the risks associated <a href="https://jordangazette.com/air-arabia-rolls-out-ramadan-sale-with-up-to-40-discounts/”>with supply chain disruptions.
Under the new framework, pharmaceutical manufacturers operating in the UAE market will no longer be permitted to rely on a single exclusive local agent for the distribution of a registered medical product. Instead, companies must appoint multiple agents, creating a more competitive and resilient distribution structure.
Emirates Drug Establishment Announces Measures to End the Monopoly of Medical Products in the UAE pic.twitter.com/ID75O9xahu
— UAEGOV (@UAEmediaoffice) February 24, 2026
According to the announcement, the mechanism seeks to address monopolistic dynamics that can limit market access, constrain pricing flexibility and increase vulnerability to supply interruptions — particularly during emergencies and global crises. By diversifying distribution channels, regulators aim to safeguard consistent product availability across hospitals, pharmacies and healthcare providers nationwide.